"听说房贷可以返点，求联系。"上海的西米在某社交平台了解到个人住房贷款有返点的情况后，发布了 这样一则帖子。发帖后，有人提醒她小心被骗，有人表示从未听说，而更多留言则来自中介员工。 上海某房地产销售代理告诉时代周报记者："上海办理100万房贷可以拿5000元，目前某国有大行、某城 商行的比例是千五（0.5%），某股份制商业银行是千四（0.4%），而另一家国有大行的返点比例是 0.3%。" 所谓"房贷返点"，是银行为争夺房贷业务衍生出的一种促销手段。银行与地产中介机构合作，对于中介 机构推荐的客户，银行按照个人按揭贷款金额的一定比例，向地产中介支付佣金。该现象多存在于二手 房交易中。 上述房地产销售代理向时代周报记者表示，一手房也能操作，但需要开发商提供担保函，很多开发商不 愿意提供。 "房贷返点"早已不是新事物。早在2010年，中国银行业协会就已印发《关于规范做好个人房地产按揭贷 款业务维护市场秩序的自律共识的通知》，直指银行业金融机构为争取房贷业务资源向房贷中介支付 高"返点"费用，引发银行间恶性竞争的问题。 近期，上海、广东、浙江、安徽等地金融监管局、银行业协会更是提出"反内卷"相关举措，除了房贷返 点， ...

Core Viewpoint - New Tian Pharmaceutical continues to face declining performance in the first half of the year, with both revenue and net profit experiencing significant drops, primarily due to rising raw material costs and a noticeable decrease in product sales [2][4]. Financial Performance - The company reported a revenue of approximately 358 million yuan, a year-on-year decrease of 18.88% [4]. - Net profit attributed to shareholders was about 5.77 million yuan, down 80.99% year-on-year [4]. - The sales of gynecological products, which account for over 70% of revenue, fell by 16.61% [4][5]. Product Sales Breakdown - Gynecological products generated approximately 266 million yuan, representing a 16.61% decline [5]. - Urological products saw a revenue drop of 26.8%, totaling around 61 million yuan [5]. - Revenue from heat-clearing and detoxifying products decreased by 23.04%, amounting to approximately 28 million yuan [5]. - Other product categories experienced a 7% increase in revenue, totaling about 3.61 million yuan, but this only accounted for 1.01% of total revenue [4][5]. Cost and Expense Management - Rising raw material prices have been a persistent issue, with raw material costs accounting for 58.35% of total costs in 2023 [7]. - The company has been actively reducing sales expenses, with a 17.79% decrease in 2023 and a 15.06% decrease in 2024 [10]. - In the first half of 2025, sales expenses were approximately 159 million yuan, down 11.61% year-on-year [10]. Regulatory and Ethical Concerns - New Tian Pharmaceutical's subsidiary faced allegations of commercial bribery, which has led to increased scrutiny and pressure on sales strategies [9]. - The company has acknowledged the situation but has not provided detailed public comments on the allegations [9].

Core Viewpoint - The article discusses a significant corruption case involving a senior executive from a Shanghai-based internet company, specifically related to bribery in logistics operations, highlighting the systemic issues within the industry [1][3]. Group 1: Case Details - Seven suspects were arrested in connection with the bribery case, with the total amount involved exceeding 40 million yuan [1]. - The main suspect, Han Liu, a former logistics supervisor at Ele.me, was implicated in accepting bribes from suppliers in exchange for logistics service qualifications in various cities [1][3]. - The investigation revealed that Han and his accomplices engaged in corrupt practices over a period of less than two years, receiving bribes more than 30 times [1]. Group 2: Supplier Dynamics - Suppliers who bribed Han did so for various reasons, including retaining their supplier status after failing assessments and seeking better business conditions [3]. - Han and his associates leveraged their positions to provide preferential treatment to bribing suppliers, offering them business advantages beyond the platform's operational rules [3]. Group 3: Investigation and Response - The police conducted a coordinated operation with Zhejiang authorities to apprehend the suspects after gathering substantial evidence [3]. - Ele.me's internal investigation led to the reporting of Han's misconduct to law enforcement, emphasizing the company's commitment to integrity and compliance [5]. Group 4: Executive Background - Han Liu, born in the 1980s, previously worked at JD.com and joined Alibaba in 2019, eventually becoming the CEO of Ele.me in March 2024 [5][6]. - In February 2025, Ele.me's chairman announced that he would take over the CEO role, with Han focusing on the logistics center [6].

Core Viewpoint - The article discusses a significant corruption case involving a senior executive from a Shanghai-based internet company, specifically related to bribery and misconduct in logistics operations, highlighting the extent of the financial misconduct and the subsequent police investigation [1][3][4]. Group 1: Case Overview - In July 2023, Shanghai police reported the arrest of seven individuals involved in a bribery case, with the total amount exceeding 40 million yuan (approximately 5.6 million USD) [1]. - The case centers around Han Liu, a former logistics supervisor at Ele.me, who was implicated in accepting bribes from suppliers in exchange for logistics business qualifications across multiple cities [1][3]. Group 2: Modus Operandi - Han Liu and two accomplices colluded to leverage their authority over logistics operations, facilitating suppliers' access to business opportunities while demanding a share of their profits [1][3]. - The investigation revealed that suppliers engaged in bribery to either retain their business status or improve their operational conditions, with Han Liu providing preferential treatment to those who complied [3]. Group 3: Investigation and Arrest - The police discovered that the bribery methods employed by Han Liu and his associates were highly covert, involving frequent lavish meals with suppliers and the strategic concealment of illicit funds across various rental properties [3]. - Following a thorough investigation, police conducted a coordinated operation in June 2025, resulting in the arrest of Han Liu and four supplier representatives for their involvement in bribery and corruption [3][4]. Group 4: Company Response - In June 2023, Ele.me acknowledged the investigation into Han Liu, stating that the company had conducted an internal review and reported the findings to law enforcement, emphasizing its commitment to integrity and compliance [4].

Core Viewpoint - The article highlights a significant case of commercial bribery involving a senior executive from Ele.me, a major internet company in Shanghai, leading to the arrest of seven suspects and the involvement of over 40 million yuan in illicit funds [1][8][14]. Group 1: Case Details - The executive involved, Han Liu, was the former logistics head at Ele.me and was found to have accepted bribes while in office [2][18]. - The investigation began after Ele.me conducted an internal review and reported the findings to the police through the "Blue Whale" enterprise protection station [4][6]. - Han and his accomplices allegedly colluded to help suppliers gain logistics delivery qualifications in exchange for bribes, totaling over 40 million yuan in less than two years [7][8]. Group 2: Police Actions and Findings - Following the report, the Shanghai Economic Crime Investigation Team initiated an investigation, leading to the arrest of Han and four supplier heads involved in the bribery [13][14]. - The police discovered that the bribery methods were covert, with the suspects frequently accepting lavish meals from suppliers while hiding the illicit funds in various rented properties [11][12]. - The police emphasized the need for a robust legal framework and internal controls within companies to prevent such economic crimes [15][16]. Group 3: Broader Implications - The case underscores the detrimental impact of commercial bribery on fair market practices and consumer rights, prompting law enforcement to maintain a stringent stance against economic crimes [15][16]. - The Shanghai police reported a 6.3% decrease in criminal cases this year, indicating effective crime prevention strategies [25][26]. - The police are focusing on various types of economic crimes, including internal corruption within internet companies, as part of their ongoing efforts to enhance public safety [26][27].

Core Viewpoint - The article highlights a significant case of commercial bribery involving a former executive of an internet company in Shanghai, revealing the extent of corruption and its impact on market integrity and consumer rights [1][2]. Group 1: Case Details - A former vice president of a Shanghai internet company was found to have accepted bribes totaling over 40 million yuan (approximately 5.6 million USD) from suppliers in exchange for favorable logistics business opportunities [1]. - The investigation began after the company self-reported the misconduct, leading to a police inquiry that uncovered a network of collusion among three individuals who exploited their positions to benefit suppliers [1][2]. - The suspects were involved in over 30 instances of accepting bribes within a two-year period, using their authority to manipulate supplier qualifications and business resources [1][2]. Group 2: Investigation and Legal Actions - The police conducted a coordinated operation with Zhejiang authorities, resulting in the arrest of seven individuals, including the main suspects and four supplier representatives who engaged in bribery [2]. - The suspects are facing charges of bribery and corruption, with the investigation ongoing to uncover further details of the illicit activities [2]. - The case underscores the serious implications of commercial bribery on fair market practices and consumer rights, prompting law enforcement to maintain a stringent stance against economic crimes [2].

Core Viewpoint - The article highlights a significant case of commercial bribery involving executives of an internet company in Shanghai, leading to the arrest of seven suspects and the recovery of over 40 million yuan in illicit funds [1][2]. Group 1: Case Details - The investigation was initiated after the company self-reported the misconduct of former vice president Han and others, who were found to have accepted bribes while facilitating logistics business for suppliers [1]. - From July 2023, Han and two accomplices colluded to leverage their authority over logistics and supplier management, resulting in the acquisition of logistics qualifications for multiple suppliers across major cities [1][2]. - Over a period of less than two years, the suspects received bribes exceeding 40 million yuan from suppliers, with some payments being based on profit-sharing agreements [1][2]. Group 2: Methods and Implications - The bribery methods employed by the suspects were notably covert, involving frequent supplier banquets and the dispersal of illicit funds across various rental properties to avoid detection [2]. - The case underscores the detrimental impact of commercial bribery on fair market practices and consumer rights, prompting law enforcement to maintain a stringent stance against economic crimes affecting enterprises [2].

Core Viewpoint - Hainan Yangpu Junhe Pharmaceutical Co., Ltd. was fined a total of 424,207.36 yuan for commercial bribery, which included the confiscation of illegal gains amounting to 224,207.36 yuan and a fine of 200,000 yuan, due to its actions of providing benefits to medical institution staff in the drug sales business [2][4]. Summary by Relevant Sections Administrative Penalty - The penalty was issued by the Danzhou Market Supervision Administration on July 1, 2025, under the administrative penalty decision number Danzhou Supervision Penalty (2025) No. 70 [3]. - The total amount of the penalty includes 224,207.36 yuan in confiscated illegal gains and a fine of 200,000 yuan, totaling 424,207.36 yuan [3]. Violations and Legal Basis - The company violated Article 7 of the Anti-Unfair Competition Law of the People's Republic of China, specifically regarding commercial bribery [3][4]. - The investigation revealed that from 2016 to 2021, the company engaged in bribery to secure drug sales opportunities with the Lingao County People's Hospital [4]. Specific Bribery Incidents - In the second half of 2019, the then-shareholder and general manager of the company, Shi Moujun, gifted 10,000 yuan in cash to the then-deputy director of Lingao County People's Hospital, Xie Mouliang [4]. - From September 2020 to June 2021, the business manager Liang Mou bribed Xie Mouliang with a total of 22,000 yuan in six installments, which facilitated drug procurement processes, involving total drug sales revenue exceeding 6.94 million yuan [4]. Related Cases and Industry Context - The former deputy director of Lingao County People's Hospital, Xie Mouliang, was also investigated and removed from office for serious violations related to accepting bribes in drug procurement and project contracting [4]. - The company, established in 2019 with a registered capital of 20 million yuan, has faced administrative penalties previously, including the revocation of the drug business license of its affiliated company in June 2024 [4]. Industry Trends and Regulatory Actions - The pharmaceutical industry has seen a rise in commercial bribery cases, prompting regulatory bodies to enhance governance through special rectification and credit punishment measures [5]. - The implementation of the medical insurance drug traceability code system starting July 1, 2025, aims to reduce gray areas in drug circulation from a technical perspective [5]. - Experts emphasize that such cases undermine fair market competition and may affect drug quality and medical safety, necessitating legal deterrence and institutional innovation for long-term governance [5][6].

Core Viewpoint - The dispute between Weihai Baihe Biotechnology Co., Ltd. (Baihe) and Shandong Hailaiyunshi Co., Ltd. (Hailaiyunshi) has raised concerns over potential commercial bribery, impacting Baihe's market image and future prospects [1][2][3] Group 1: Dispute Background - The conflict originated from a discarded contract signed in December 2020 for the production of oat bran and other meal replacement products [1] - Baihe completed production tasks as per orders in January and March 2021, but Hailaiyunshi ceased issuing new production instructions by the end of March 2021 [1] - In 2024, Baihe claimed that a batch of raw materials prepared for the contract had expired and demanded compensation from Hailaiyunshi, leading to a lawsuit after failed negotiations [1] Group 2: Evidence of Bribery - During the lawsuit, Hailaiyunshi's lawyer discovered a record of a payment of 0.6 yuan per box to Baihe's procurement personnel, potentially amounting to 360,000 yuan based on an annual purchase volume of 600,000 boxes [2] - Key personnel at Baihe, including the vice president and auditors, approved this arrangement, raising suspicions of commercial bribery [2][3] Group 3: Company Performance and Responsibilities - Baihe, known as the "first stock of nutritional health food OEM," reported a revenue of 801 million yuan in 2024, with 84% of this revenue coming from its OEM business [5] - The company faced a revenue decline of 8.02% year-on-year and a net profit drop of 17.60% in 2024, attributed to global economic fluctuations and domestic market adjustments [5] - Baihe is obligated to disclose information regarding the incident, internal investigations, and corrective measures to the market and investors [5]

Core Viewpoint - Jinan Runda Biotechnology Co., Ltd. was fined 600,000 yuan for commercial bribery related to the sale of automatic coagulation analyzers and associated consumables [1][4]. Company Summary - Jinan Runda was found to have engaged in commercial bribery by selling automatic coagulation analyzers and related consumables at low prices to hospitals, thereby gaining more trading opportunities [1][3]. - The company was established in 2014, with a registered capital of 50.5 million yuan, and is primarily owned by Shanghai Runda Medical Technology Co., Ltd., which holds a 70% stake [5]. - The legal representative of Jinan Runda is Li Jie [5]. Parent Company Summary - Shanghai Runda Medical Technology Co., Ltd. was founded in 1999 and went public in 2015. As of March 10, 2025, the largest shareholder is Hangzhou Gongshu District State-owned Investment Group Co., Ltd., holding 19.22% [6]. - Runda Medical acknowledged the commercial bribery incident and stated that it is cooperating with regulatory authorities for investigation and corrective actions [6]. - The company is involved in the IVD (in vitro diagnostics) distribution and service industry, providing diagnostic products and technical support to medical laboratories [6]. Financial Performance - Runda Medical's performance has declined significantly in recent years. In 2024, the company reported revenue of 8.312 billion yuan, a decrease of 9.13% year-on-year, and net profit dropped from 273 million yuan to 55 million yuan, a decline of 79.77% [6][8]. - In the first quarter of 2025, the company reported revenue of 1.662 billion yuan, down 19.81% year-on-year, and a net loss of 69 million yuan, marking a 406.40% decline [8][9]. - The company's total expenses (sales, management, and financial) reached 1.634 billion yuan in 2024, accounting for 19.66% of revenue, an increase of 0.62 percentage points year-on-year [8].